A myeloid tumor suppressor role for NOL3

Despite the identification of several oncogenic driver mutations leading to constitutive JAK–STAT activation, the cellular and molecular biology of myeloproliferative neoplasms (MPN) remains incompletely understood. Recent discoveries have identified underlying disease-modifying molecular aberrations contributing to disease initiation and progression. Here, we report that deletion of Nol3 (Nucleolar protein 3) in mice leads to an MPN resembling primary myelofibrosis (PMF). Nol3−/− MPN mice harbor an expanded Thy1+LSK stem cell population exhibiting increased cell cycling and a myelomonocytic differentiation bias. Molecularly, this phenotype is mediated by Nol3−/−-induced JAK–STAT activation and downstream activation of cyclin-dependent kinase 6 (Cdk6) and Myc. Nol3−/− MPN Thy1+LSK cells share significant molecular similarities with primary CD34+ cells from PMF patients. NOL3 levels are decreased in CD34+ cells from PMF patients, and the NOL3 locus is deleted in a subset of patients with myeloid malignancies. Our results reveal a novel genetic PMF-like mouse model and identify a tumor suppressor role for NOL3 in the pathogenesis of myeloid malignancies.

[1]  M. Cazzola,et al.  miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. , 2014, Blood.

[2]  K. Coombes,et al.  Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. , 2011, Blood.

[3]  R. Verhaak,et al.  A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. , 2007, The Journal of clinical investigation.

[4]  V. Najfeld,et al.  Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms. , 2009, Experimental hematology.

[5]  A. Mcmahon,et al.  Cloning and characterization of cDNAs for novel proteins with glutamic acid-proline dipeptide tandem repeats. , 1996, Biochimica et biophysica acta.

[6]  A. Tefferi,et al.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 , 2010, Leukemia.

[7]  P. Chambon,et al.  A Microenvironment-Induced Myeloproliferative Syndrome Caused by Retinoic Acid Receptor γ Deficiency , 2007, Cell.

[8]  S. Korsmeyer,et al.  Inhibition of both the extrinsic and intrinsic death pathways through nonhomotypic death-fold interactions. , 2004, Molecular cell.

[9]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[10]  M. Andreeff,et al.  Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML , 2013, Apoptosis.

[11]  S. Ben-Neriah,et al.  Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. , 2012, Blood.

[12]  A. Tichelli,et al.  Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. , 2010, Blood.

[13]  J. Pollard,et al.  Apoptosis inhibitor ARC promotes breast tumorigenesis, metastasis, and chemoresistance. , 2011, Cancer research.

[14]  木内 庸雄.  STAT3 is required for the gp130 - mediated full activation of the c-myc gene , 1999 .

[15]  R. Kralovics,et al.  Clonal analysis of deletions on chromosome 20 q and JAK 2V 617 F in MPD suggests that del 20 q acts independently and is not one of the predisposing mutations for JAK 2V 617 F , 2009 .

[16]  M. Halushka,et al.  A Critical Role for the Protein Apoptosis Repressor With Caspase Recruitment Domain in Hypoxia-Induced Pulmonary Hypertension , 2011, Circulation.

[17]  F. Al-Shahrour,et al.  Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. , 2016, Cancer discovery.

[18]  B. Swolin,et al.  Patients with idiopathic myelofibrosis show increased CD34+ cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia , 2002, European journal of haematology.

[19]  M. Crow,et al.  Apoptosis repressor with caspase recruitment domain (ARC) is expressed in cancer cells and localizes to nuclei , 2005, FEBS letters.

[20]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[21]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[22]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[23]  A. Tefferi.  JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. , 2012, Blood.

[24]  M. Crow,et al.  The Apoptosis Inhibitor ARC Alleviates the ER Stress Response to Promote β-Cell Survival , 2012, Diabetes.

[25]  G. Superti-Furga,et al.  Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.

[26]  M. Cazzola,et al.  Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post‐ASH symposium , 2012, American journal of hematology.

[27]  I. Ellis,et al.  Abstract 313: Regulation of p53 Tetramerization and Nuclear Export by ARC , 2006 .

[28]  T. Hirano,et al.  STAT3 orchestrates contradictory signals in cytokine‐induced G1 to S cell‐cycle transition , 1998, The EMBO journal.

[29]  Kairong Cui,et al.  Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. , 2012, Immunity.

[30]  S. Chen,et al.  ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Harvey F. Lodish,et al.  Lnk Inhibits Tpo–mpl Signaling and Tpo-mediated Megakaryocytopoiesis , 2004, The Journal of experimental medicine.

[32]  R. Kralovics,et al.  Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. , 2006, Blood.

[33]  T. Barbui,et al.  Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. , 2014, Blood.

[34]  J. Adamson,et al.  Polycythemia vera: stem-cell and probable clonal origin of the disease. , 1976, The New England journal of medicine.

[35]  A. Tefferi,et al.  Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Ayalew Tefferi,et al.  Myeloproliferative Neoplasms A Contemporary Review , 2015 .

[37]  E. Hatzimichael,et al.  Serum interleukin (IL)‐1, IL‐2, sIL‐2Ra, IL‐6 and thrombopoietin levels in patients with chronic myeloproliferative diseases , 2005, British journal of haematology.

[38]  Wanke Zhao,et al.  JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines , 2012, Experimental Hematology & Oncology.

[39]  S. Armstrong,et al.  Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis. , 2011, Blood.

[40]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[41]  G. Kung,et al.  A novel role for the apoptosis inhibitor ARC in suppressing TNFα-induced regulated necrosis , 2014, Cell Death and Differentiation.

[42]  J. D. Fitzpatrick,et al.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.

[43]  P. Fialkow,et al.  Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. , 1978, Blood.

[44]  N. Komatsu.  [Myeloproliferative neoplasms]. , 2013, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[45]  J. Mariadason,et al.  ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer , 2008, Cell cycle.

[46]  Sophia Pinz,et al.  Signal transducer and activator of transcription STAT5 is recruited to c-Myc super-enhancer , 2016, BMC Molecular Biology.

[47]  R. Kralovics,et al.  Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. , 2009, Blood.

[48]  J. Pollard,et al.  ARC, an apoptosis suppressor limited to terminally differentiated cells, is induced in human breast cancer and confers chemo- and radiation-resistance , 2005, Cell Death and Differentiation.

[49]  Erin F. Simonds,et al.  Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. , 2010, Blood.

[50]  Sheng Wei,et al.  IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. , 2015, Blood.

[51]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[52]  B. Neel,et al.  Flow-Cytometric Phosphoprotein Analysis Reveals Agonist and Temporal Differences in Responses of Murine Hematopoietic Stem/Progenitor Cells , 2008, PloS one.

[53]  T. Hirano,et al.  Stat3 Is Required for the Gp130-mediated Full Activation of the C-myc Gene , 1999 .

[54]  G. Faguet,et al.  Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. , 1981, Blood.

[55]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[56]  R. Mesa,et al.  Current Outlook on Molecular Pathogenesis and Treatment of Myeloproliferative Neoplasms , 2012, Molecular Diagnosis & Therapy.

[57]  S. Orkin,et al.  Rb Regulates Interactions between Hematopoietic Stem Cells and Their Bone Marrow Microenvironment , 2007, Cell.

[58]  David W. Johnson,et al.  Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways. , 2016, Biochemical and biophysical research communications.

[59]  M. Andreeff,et al.  Apoptosis repressor with caspase recruitment domain modulates second mitochondrial‐derived activator of caspases mimetic‐induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia , 2014, British journal of haematology.